New clinical trials are underway for psoriasis medications.
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore the therapeutic use of guselkumab for psoriatic arthritis, but also aims to compare the effectiveness of guselkumab with Cosentyx (secukinumab) for moderate to severe plaque-type psoriasis.
Guselkumab is a monoclonal antibody that targets a well-known molecule involved in the progression of psoriasis, interleukin-23. Developed by Janssen and produced by MorphoSys using its HuCAL antibody library technology, this potential therapy was shown to be effective and safe for the treatment of psoriatic arthritis (PsA) and plaque psoriasis.
Previous results from VOYAGE 1 (NCT02207231), VOYAGE 2 (NCT02207244) and NAVIGATE (NCT02203032) Phase 3 clinical trials have already demonstrated the superiority of guselkumab over Humira (adalimumab) and Stelara (ustekinumab) as treatment for moderate to severe plaque psoriasis.
Read full article: Plaque Psoriasis, Psoriatic Arthritis Focus of Phase 3 Guselkumab Trials
|Read Full Article: Plaque Psoriasis, Psoriatic Arthritis Focus of Phase 3 Guselkumab Trials|